---
document_datetime: 2026-01-09 14:54:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_en.pdf
document_name: tysabri-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0426197
conversion_datetime: 2026-01-10 11:38:58.658966
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging        | Content         | Pack size                                 |
|------------------|-------------------|------------|---------------------------------------|---------------------------|----------------------------|-----------------|-------------------------------------------|
| EU/1/06/346/001  | Tysabri           | 300 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass)               | 15 ml (20mg/mL) | 1vial                                     |
| EU/1/06/346/002  | Tysabri           | 150 mg     | Solution for injection                | Subcutaneous use          | Pre-filled syringe (glass) | 1 ml (150mg/mL) | 2 pre-filled syringes                     |
| EU/1/06/346/003  | Tysabri           | 150 mg     | Solution for injection                | Subcutaneous use          | Pre-filled syringe (glass) | 1 ml (150mg/mL) | 6 (3 x 2) pre-filled syringes (multipack) |